S&P 500   3,296.37 (+0.05%)
DOW   26,751.01 (+0.32%)
QQQ   269.15 (-0.09%)
AAPL   436.87 (+0.26%)
MSFT   211.65 (-2.26%)
FB   248.91 (-1.21%)
GOOGL   1,470.31 (-0.84%)
AMZN   3,110.74 (-0.04%)
NVDA   445.06 (+1.06%)
CGC   19.12 (+0.31%)
BABA   261.73 (+1.47%)
TSLA   1,471.84 (-0.89%)
MU   51.09 (+1.39%)
GE   6.15 (+0.65%)
AMD   84.62 (+8.95%)
T   30.04 (+1.42%)
F   6.84 (+2.24%)
ACB   10.60 (+1.73%)
GILD   70.72 (-1.42%)
NFLX   507.37 (+1.75%)
DIS   117.54 (+1.02%)
BAC   24.98 (-0.04%)
BA   165.49 (+1.98%)
S&P 500   3,296.37 (+0.05%)
DOW   26,751.01 (+0.32%)
QQQ   269.15 (-0.09%)
AAPL   436.87 (+0.26%)
MSFT   211.65 (-2.26%)
FB   248.91 (-1.21%)
GOOGL   1,470.31 (-0.84%)
AMZN   3,110.74 (-0.04%)
NVDA   445.06 (+1.06%)
CGC   19.12 (+0.31%)
BABA   261.73 (+1.47%)
TSLA   1,471.84 (-0.89%)
MU   51.09 (+1.39%)
GE   6.15 (+0.65%)
AMD   84.62 (+8.95%)
T   30.04 (+1.42%)
F   6.84 (+2.24%)
ACB   10.60 (+1.73%)
GILD   70.72 (-1.42%)
NFLX   507.37 (+1.75%)
DIS   117.54 (+1.02%)
BAC   24.98 (-0.04%)
BA   165.49 (+1.98%)
S&P 500   3,296.37 (+0.05%)
DOW   26,751.01 (+0.32%)
QQQ   269.15 (-0.09%)
AAPL   436.87 (+0.26%)
MSFT   211.65 (-2.26%)
FB   248.91 (-1.21%)
GOOGL   1,470.31 (-0.84%)
AMZN   3,110.74 (-0.04%)
NVDA   445.06 (+1.06%)
CGC   19.12 (+0.31%)
BABA   261.73 (+1.47%)
TSLA   1,471.84 (-0.89%)
MU   51.09 (+1.39%)
GE   6.15 (+0.65%)
AMD   84.62 (+8.95%)
T   30.04 (+1.42%)
F   6.84 (+2.24%)
ACB   10.60 (+1.73%)
GILD   70.72 (-1.42%)
NFLX   507.37 (+1.75%)
DIS   117.54 (+1.02%)
BAC   24.98 (-0.04%)
BA   165.49 (+1.98%)
S&P 500   3,296.37 (+0.05%)
DOW   26,751.01 (+0.32%)
QQQ   269.15 (-0.09%)
AAPL   436.87 (+0.26%)
MSFT   211.65 (-2.26%)
FB   248.91 (-1.21%)
GOOGL   1,470.31 (-0.84%)
AMZN   3,110.74 (-0.04%)
NVDA   445.06 (+1.06%)
CGC   19.12 (+0.31%)
BABA   261.73 (+1.47%)
TSLA   1,471.84 (-0.89%)
MU   51.09 (+1.39%)
GE   6.15 (+0.65%)
AMD   84.62 (+8.95%)
T   30.04 (+1.42%)
F   6.84 (+2.24%)
ACB   10.60 (+1.73%)
GILD   70.72 (-1.42%)
NFLX   507.37 (+1.75%)
DIS   117.54 (+1.02%)
BAC   24.98 (-0.04%)
BA   165.49 (+1.98%)
Log in

OTCMKTS:CTTCCalmare Therapeutics Stock Price, Forecast & News

$0.06
0.00 (0.00 %)
(As of 08/4/2020 02:56 PM ET)
Add
Compare
Today's Range
$0.06
Now: $0.06
$0.06
50-Day Range
$0.06
MA: $0.09
$0.12
52-Week Range
$0.06
Now: $0.06
$0.20
VolumeN/A
Average Volume3,200 shs
Market Capitalization$1.91 million
P/E RatioN/A
Dividend YieldN/A
Beta0.65
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CTTC
CUSIPN/A
Phone203-368-6044

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees7
Market Cap$1.91 million
Next Earnings DateN/A
OptionableNot Optionable
$0.06
0.00 (0.00 %)
(As of 08/4/2020 02:56 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTTC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Calmare Therapeutics (OTCMKTS:CTTC) Frequently Asked Questions

How has Calmare Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Calmare Therapeutics' stock was trading at $0.0995 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CTTC stock has decreased by 36.7% and is now trading at $0.0630.
View which stocks have been most impacted by Coronavirus
.

Has Calmare Therapeutics been receiving favorable news coverage?

Media headlines about CTTC stock have trended very negative recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Calmare Therapeutics earned a news impact score of -3.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the near future.
View the latest news about Calmare Therapeutics
.

Who are some of Calmare Therapeutics' key competitors?

What other stocks do shareholders of Calmare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calmare Therapeutics investors own include Idera Pharmaceuticals (IDRA), Brainstorm Cell Therapeutics (BCLI), Costco Wholesale (COST), Blue Apron (APRN), Aphria (APHA), Arista Networks (ANET), Amgen (AMGN), Advanced Micro Devices (AMD), Akers Biosciences (AKER) and AdvisorShares Vice ETF (ACT).

Who are Calmare Therapeutics' key executives?

Calmare Therapeutics' management team includes the following people:
  • Mr. Conrad F. Mir, Pres, CEO & Director (Age 50)
  • Mr. Thomas Philip Richtarich M.B.A., Chief Financial Officer (Age 66)
  • Ms. Donna J. Mays, Mang. of Admin. Services
  • Dr. Stephen J. D'Amato, Chief Medical Officer & Member of Medical Advisory Board (Age 71)
  • Mr. William Lipford, Division Head of Product Sales

What is Calmare Therapeutics' stock symbol?

Calmare Therapeutics trades on the OTCMKTS under the ticker symbol "CTTC."

How do I buy shares of Calmare Therapeutics?

Shares of CTTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Calmare Therapeutics' stock price today?

One share of CTTC stock can currently be purchased for approximately $0.06.

How big of a company is Calmare Therapeutics?

Calmare Therapeutics has a market capitalization of $1.91 million. Calmare Therapeutics employs 7 workers across the globe.

What is Calmare Therapeutics' official website?

The official website for Calmare Therapeutics is www.calmaretherapeutics.com.

How can I contact Calmare Therapeutics?

Calmare Therapeutics' mailing address is 1375 KINGS HIGHWAY EAST SUITE 400, FAIRFIELD CT, 06824. The company can be reached via phone at 203-368-6044 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.